Korman D B, Boronovskaia L E, Maslova I A, Andreeva E V, Seregina G V
Vopr Onkol. 2008;54(5):639-42.
Recombinant preparation of human G-CSF-Leukostim (Russia)--(filgrastim; analog of Neupogen)--was administered in 31 patients (breast cancer--28; ovarian carcinoma--3) to treat or prevent chemotherapy-induced neutropenia. The latter was aborted after 2-6 injections. Due to use of Leukostim, another course of chemotherapy (10 cycles) was successfully used in 5 breast cancer patients: no inhibition of hemopoiesis followed although the patients had suffered acute and persistent neutropenia from previous chemotherapy. No adverse side-effects of Leukostim administration were reported.
人粒细胞集落刺激因子-白细胞刺激因子(俄罗斯)(非格司亭;优保津类似物)的重组制剂用于31例患者(乳腺癌28例;卵巢癌3例),以治疗或预防化疗引起的中性粒细胞减少。在注射2 - 6次后,中性粒细胞减少得到缓解。由于使用了白细胞刺激因子,5例乳腺癌患者成功地进行了另一疗程的化疗(10个周期):尽管这些患者先前化疗时曾出现急性和持续性中性粒细胞减少,但随后并未出现造血抑制。未报告使用白细胞刺激因子的不良副作用。